Guselkumab efficacy and safety through 5 years among psoriasis patients with and without metabolic syndrome at baseline: Results from VOYAGE 1 and VOYAGE 2

被引：0
|
作者：
Merola, Joseph F. [1 ]
Thaci, Diamant [2 ]
Choi, Olivia [3 ]
Chan, Daphne [3 ]
Yang, Ya-Wen [4 ]
Miller, Megan [5 ]
You, Yin [5 ]
Li, Shu [5 ]
Blauvelt, Andrew [6 ]
Puig, Luis [7 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA
[2] Univ Lubeck, Lubeck, Germany
[3] Janssen Sci Affairs LLC, Horsham, PA USA
[4] Janssen Pharmaceut Companies Johnson & Johnson, Immunol Global Med Affairs, Horsham, PA USA
[5] Janssen Res & Dev LLC, Spring House, PA USA
[6] Oregon Med Res Ctr, Portland, OR USA
[7] Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2022年 / 87卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
33055
引用
收藏
页码：AB170 / AB170
页数：1
相关论文
共 50 条
  • [31] Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2
    Puig, Luis
    Wu, Jashin J.
    Gooderham, Melinda J.
    You, Yin
    Shen, Yaung-Kaung
    Randazzo, Bruce
    Kerdel, Francisco
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2021, 32 (05) : 484 - 491
  • [32] MAINTENANCE OF RESPONSE THROUGH 5 YEARS OF CONTINUOUS GUSELKUMAB TREATMENT: RESULTS FROM THE PHASE-3 VOYAGE 1 TRIAL
    Griffiths, C. E. M.
    Papp, K.
    Song, M.
    Miller, M.
    You, Y.
    Shen, Y. K.
    Blauvelt, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1297 - 1298
  • [33] Malignancy rates through 5 years of follow-up in guselkumab-treated patients with moderate to severe psoriasis: Results from the VOYAGE 1 and 2 trials and comparisons to general populations
    Blauvelt, Andrew
    Langley, Richard G.
    Ho, Vincent
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB79 - AB79
  • [34] Long-term safety of guselkumab, an anti-interleukin-23p19 monoclonal antibody: results from the VOYAGE 1 and VOYAGE 2 trials with up to 5 years of treatment
    Blauvelt, A.
    Gordon, K.
    Griffiths, C.
    Papp, K.
    Foley, P.
    Song, M.
    Miller, M.
    Shen, Y. -K.
    You, Y.
    Ramachandran, P.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E52 - E52
  • [35] Maintenance of response through up to 5-years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 phase 3 trial
    Reich, Kristian
    Armstrong, April W.
    Langley, Richard
    Vender, Ron
    Foley, Peter
    Song, Michael
    Miller, Megan
    You, Yin
    Shen, Yaung-Kaung
    Gordon, Kenneth B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB163 - AB163
  • [36] Maintenance of response with guselkumab of up to 3 years' treatment: Voyage 1 trial of patients with plaque psoriasis
    Griffiths, C.
    Papp, K.
    Song, M.
    Randazzo, B.
    Li, S.
    Shen, Y.
    Han, C.
    Blauvelt, A.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 45 - 45
  • [37] Comparable and consistent efficacy responses with up to 3 years of guselkumab treatment in patients with moderate-to-severe plaque psoriasis regardless of prior treatment: Pooled analysis from the VOYAGE 1 and VOYAGE 2 trials
    Gordon, K.
    Guenther, L.
    Pinter, A.
    Choe, Y. -B.
    Song, M.
    Li, S.
    Fakharzadeh, S.
    Shen, Y-K.
    Tsai, T-F.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB185 - AB185
  • [38] Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials
    Puig, L.
    Tsai, T. -F.
    Bhutani, T.
    Uy, J.
    Ramachandran, P.
    Song, M.
    You, Y.
    Gooderham, M.
    Lebwohl, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (08) : 1744 - 1749
  • [39] Efficacy responses across subgroups of patients with moderate-to-severe plaque psoriasis treated with guselkumab, an anti-interleukin-23p19 monoclonal antibody: results from VOYAGE 1 through 5 years
    Thaci, D.
    Foley, P.
    Puig, L.
    Merola, J. F.
    Miller, M.
    You, Y.
    Shen, Y. -K.
    Yang, Y. -W.
    Blauvelt, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E51 - E51
  • [40] Characterization of super responders to guselkumab treatment in moderate to severe psoriasis: Results from the VOYAGE 1 and 2 clinical trials
    Reich, Kristian
    Strober, Bruce
    Langley, Richard
    Song, Michael
    Shen, Yaung-Kaung
    You, Yin
    Foley, Peter
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB145 - AB145
12345